MajorCardiac glycosides (digitalis)×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
Digoxin is a substrate of the transporter P-glycoprotein (P-gp) in intestinal absorption, renal tubular secretion and biliary excretion, so drugs that inhibit P-gp can change its levels (digoxin label, US Food and Drug Administration, FDA). Ranolazine is a moderate to strong P-gp inhibitor, and digoxin levels rose on average 1.5-fold with it (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). In healthy volunteers taking ranolazine 1000 mg twice daily and digoxin 0.125 mg daily, digoxin levels rose by 50%, while digoxin did not significantly change ranolazine levels (ranolazine label, FDA). Digoxin has a narrow therapeutic index (FDA). Most patients do well at 0.8–2.0 ng/mL. Above this range, signs of toxicity may be more frequent, and levels above 3.0 ng/mL are very likely toxic (digoxin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
Digoxin toxicity usually begins with premature ventricular contractions that may progress to bigeminy or trigeminy. Atrial tachycardia with atrioventricular block is particularly characteristic, and the pulse is not necessarily fast (digoxin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Loss of appetite, nausea, vomiting and diarrhoea may occur, as well as weakness, apathy, fatigue, headache, visual disturbances, depression and even psychosis (AEMPS). The most common signs of overdose are nausea, vomiting, loss of appetite and fatigue, and low potassium raises the risk of adverse reactions (digoxin label, US Food and Drug Administration, FDA). Hypoxia, low magnesium and markedly high calcium also make the heart more sensitive to digoxin (AEMPS).
Management
Reduce the digoxin dose. The table in the US digoxin label puts ranolazine (a 50% rise in digoxin levels) in the group for which the label says to measure serum digoxin before starting the combination, then reduce the digoxin dose by about 30–50% or give it less often, and continue monitoring (digoxin label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) says to monitor digoxin levels after starting and after stopping any course of ranolazine (ranolazine SmPC, European Medicines Agency, EMA). The US ranolazine label says the digoxin dose may need to be adjusted (ranolazine label, FDA). Take blood for digoxin levels just before the next dose or at least 6 hours after the last dose (digoxin label, FDA). When deciding whether symptoms are due to digoxin, consider the clinical state, serum potassium and thyroid function (digoxin label, FDA; digoxin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Check serum electrolytes and creatinine regularly in patients taking digoxin (AEMPS). The Spanish digoxin SmPCs do not name ranolazine. Their general rule is to bear in mind a possible interaction with any concomitant treatment and to measure digoxin levels when in doubt (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Lanoxin (digoxin) prescribing information (2024)– FDA label, DailyMed setid d91e3646-4c63-4512-ab22-db39c085c4dc, revised 12/2024, sections 2.5, 5.3, 7, 12.3 and 17
- AEMPS: Ficha técnica: Digoxina (nº registro 34566), secciones 4.2, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 34566, revisión 07/2026, secciones 4.2, 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.5 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (Menarini International Operations Luxembourg, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.2